

## Saskatchewan Immunization Manual Amendments **January 2022**

**Instructions:** Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

### **Chapter 10 Biological Products**

- **VAXNUEVANCE® (Merck's new Pneu-C-15 vaccine)** added to TOR second page and as a new page in this chapter.
- Moderna 12+ vaccine Precautions section
  - For individuals aged 30 and younger who are receiving their primary COVID-19 vaccine series and both Moderna and Pfizer are readily available, Pfizer is the preferred vaccine as there is a lower risk of myocarditis compared to immunization with Moderna. Individuals opting to receive Moderna shall be informed of the increased risk of myocarditis/pericarditis compared to receiving Pfizer.
  - It is unclear if people who developed myocarditis or pericarditis after a first dose of an mRNA COVID-19 vaccine are at increased risk of further adverse cardiac events following a second dose of the vaccine. **NACI continues to recommend that further doses of mRNA COVID-19 vaccines should be deferred among people who experienced myocarditis and/or pericarditis within 6 weeks of receiving a previous dose of an mRNA COVID-19 vaccine. This includes any person who had an abnormal cardiac investigation including electrocardiogram (ECG), elevated troponins, echocardiogram or cardiac MRI after a dose of an mRNA vaccine.**
  - **NACI now also recommends that those with a history compatible with pericarditis and who either had no cardiac workup or had normal cardiac investigations, can be revaccinated once they are symptom free and at least 90 days has passed since previous vaccination.** NACI will continue to monitor the evidence and update recommendations as needed.
- Pfizer +12 years vaccine Precautions section
  - For individuals aged 30 and younger who are receiving their primary COVID-19 vaccine series and both Moderna and Pfizer are readily available, Pfizer is the preferred vaccine as there is a lower risk of myocarditis compared to immunization with Moderna. Individuals opting to receive Moderna shall be informed of the increased risk of myocarditis/pericarditis compared to receiving Pfizer.
  - It is unclear if people who developed myocarditis or pericarditis after a first dose of an mRNA COVID-19 vaccine are at increased risk of further adverse cardiac events following a second dose of the vaccine. **NACI continues to recommend that further doses of mRNA COVID-19 vaccines should be deferred among people who experienced myocarditis and/or pericarditis within 6 weeks of receiving a previous dose of an mRNA COVID-19 vaccine. This includes any person who had an abnormal cardiac investigation including electrocardiogram (ECG), elevated troponins, echocardiogram or cardiac MRI after a dose of an mRNA vaccine.**
  - **NACI now also recommends that those with a history compatible with pericarditis and who either had no cardiac workup or had normal cardiac investigations, can be revaccinated once they are symptom free and at least 90 days has passed since previous vaccination.** NACI will continue to monitor the evidence and update recommendations as needed.
- Pfizer 5-11 years vaccine Preparation/Reconstitution section
  - Pre-loading Pfizer's 5-11 years vaccine into syringes for the purpose of transporting COVID-19 vaccine in exceptional circumstances has **NOT** been approved.